Event Category: Co-Partner/Other Events

–
Advanced Practice Providers Oncology Summit

APPOS is a CE conference devoted to providing the latest developments in the multidisciplinary treatment, practical patient management, and interprofessional care of oncology patients. Join us for this two-day program to earn CE credits and learn the latest clinical and practical strategies to improve care for your oncology patients and communication within your healthcare team.

–

Course Description:  BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) poses one of the most difficult challenges in urologic oncology, especially for elderly and frail patients. While radical cystectomy remains the gold standard, the treatment landscape is rapidly evolving with innovative bladder-sparing therapies that offer new hope. At the forefront of these advances is TAR-200, an intravesical…

–

Given the increasing discovery of oncogenic-driven tumors, targeted treatments with novel agents have transformed the outcomes in these patients. Clinical decision making and management therefore have become more complex. There is a need to provide an opportunity for medical oncologists, radiation oncologists, pathologists, allied health professionals, oncology nurses and pharmacists to engage in thoughtful discussions…

–

The future of radiation therapy is upon us, with game-changing advancements in adaptive radiation therapy, AI-powered treatment planning, biomarker-guided radiation delivery and precision imaging. These innovations will allow us to deliver more targeted treatments, reducing side effects while maximizing efficacy—ultimately enhancing patient quality of life. Join us on this exciting journey as we redefine the…

–

Review the latest advancements in human epidermal growth factor receptor 2 (HER2)-ultralow mBC by joining this in-depth discussion between leading pathology and medical oncology experts. Learn how a new drug indication as well as updated ASCO/CAP guidelines for HER2-low and -ultralow classifications will redefine the way patients with HER2 mBC are both diagnosed and treated.